The purpose is to conduct a dietary intervention study in which human participants will consume beverages sweetened with erythritol or aspartame, each for 2 weeks, in a randomized crossover design
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
P-selectin, a platelet surface marker, assessed as median fluorescence intensity
Timeframe: 6 weeks
P-selectin, a platelet surface marker, assessed as percentage of P-selectin positive cells
Timeframe: 6 weeks
PAC-1 (GPIIb/IIIa complex), a platelet surface marker, assessed as median fluorescence intensity
Timeframe: 6 weeks
PAC-1 (GPIIb/IIIa complex), a platelet surface marker, assessed as percentage of PAC-1 positive cells
Timeframe: 6 weeks
Annexin V, a platelet surface marker, assessed as median fluorescence intensity
Timeframe: 6 weeks
Annexin V, a platelet surface marker, assessed as percentage of annexin V positive cells
Timeframe: 6 weeks
Platelet reactivity to physiologic agonist, assessed as change in median fluorescence intensity
Timeframe: 6 weeks
Platelet aggregation in response to physiologic agonist, assessed as aggregation/min
Timeframe: 6 weeks
Platelet aggregation in response to physiologic agonist, assessed as percent of maximum aggregation
Timeframe: 6 weeks
Platelet-leukocyte interaction, assessed as platelet/leukocyte aggregate size by fluorescence mean intensity
Timeframe: 6 weeks